European Medicines Agency recommends use of bivalent boosters

7 September 2022

Health authorities in Europe have urged countries to use newly-authorized adapted COVID-19 vaccines as part of fall and winter vaccination campaigns.

Leading mRNA-based vaccines Comirnaty and Spikevax, developed by Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX), and Moderna (Nasdaq: MRNA), respectively, have been adapted to target the currently-circulating variants of the novel coronavirus.

These two new bivalent formulations would “expand the immunity versus variants of concern, especially Omicron and related sub lineages,” the European Medicines Agency said in a statement.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK